In addition, increased levels of JAK1 expression are associated with undesirable survival in patients with earlier stages (stage 1 and N0), suggesting that early-stage NSCLC patients with JAK1 overexpression may have a bleak prognosis. This evidence concerns the gene JAK1 and non-small cell lung carcinoma.